Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G<INF>1</INF> block at concentrations up to 100-fold the IC<INF>50</INF> for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound <BO>43</BO> (PD 0332991) was identified as a drug candidate for the treatment of cancer.